Iris Publishers- Open access Journal of Ophthalmology & Vision Research | Key Transcription Factors Linking Macular
Degeneration and Alzheimer’s Disease
Authored by Joseph W Eichenbaum
Alzheimer’s disease (AD) and age-related macular degeneration (AMD) have
certain pathologic features in common. Chronic
oxidative stress and neuroinflammation result in aggregate protein
deposits, extracellular drusen in AMD, extracellular and
intracellular amyloid in AD, and intracellular tau in AD, and
mitochondrial proteosomal pathway damage in both. Along with risk
factors: aging, smoking, hypertension, hypercholesterolemia, obesity,
arteriosclerosis, unhealthy diet, chronic anticholinergic use,
and latent herpetic infection, three transcription factors, NRF-2
(nuclear factor-erythroid 2) and NFKB (nuclear factor kappa B)
which regulate cellular detoxification from oxidative stress and innate
cellular immunity, respectively, and PGC-1α (peroxisome
receptor gamma coactivator), which is the master of mitochondrial
biogenesis and antioxidant control, seem to play a major role in
disease progression of AMD and AD . Neuropathology and protein marker
changes related to imbalances in NRF-2, NFKB, and PGC-
1α illustrate neurodegenerative and vision loses commensurate with NRF-2
and PGC-1α deficiencies and NFKB excess. Examining
these transcription factors in more detail may provide insights into
slowing the progression of AD and AMD.
Neuroinflammation also provokes persistent immune response, which participates in further brain and macular damage. However, studies using anti-inflammatory therapy in AD and in AMD have yielded small, mixed or inconclusive results [12-15].
Toxic protein accumulation: in AMD, drusen, (lipoprotein deposits between the basal lamina and the retinal pigment epithelial layer, RPE) and lipofuscin (from inefficient protein clearance) [3,4,13] and in AD, extracellular and intracellular amyloid and complement and intracellular tau, (because of breakdown of the blood-brain barrier from reactive oxygen species, inflammation, or local or systemic infection), may be slow burners in chronic inflammation and its sequelae [5,6,16] However, cognitive issues, (memory and learning) in AD may precede amyloid plaque and tau fibrillar aggregates by months or longer [5]. For that matter, in AMD despite impaired lysosomal degradation, lipofuscin accumulation, defects in the ubiquitin protein clearance, and mitochondria dysfunction [3], many ophthalmologists can attest to the fact that visual loss may take years to manifest.
To read more...Ophthalmology journals impact factor
To view more Journals...Iris Publishers
No comments:
Post a Comment